Typically, initial treatment for HER-2-positive breast cancer consists of a combination of monoclonal antibodies targeting HER-2—pertuzumab and trastuzumab—alongside chemotherapy based on taxanes (5, 24, 25). Here, ERBB2 is linked to breast carcinoma.